Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Tumbling Today

By Keith Speights - Apr 28, 2021 at 12:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The good news is that there isn't any bad news for the biotech.

What happened

Shares of Novavax (NVAX -1.17%) were tumbling 5.5% lower as of 12:17 p.m. EDT on Wednesday after falling as much as 8.8% earlier in the day. The stock soared in after-hours trading on Tuesday on President Biden's public comment that Novavax could soon win emergency use authorization (EUA) for its COVID-19 vaccine. So why are shares sinking today?

It's probably simply that some investors are taking profits off the table. The biotech stock soared more than 130% year to date and nearly 39% so far this month as of the Tuesday market close. 

Healthcare professional holding a syringe with needle and a vaccine vial

Image source: Getty Images.

So what

The best thing to do if you own a stock that falls with no apparent negative news is... nothing. That's especially the case with Novavax, with the company potentially drawing close to EUAs for its COVID-19 vaccine.

President Biden singled out the biotech in his remarks on Tuesday about sending vaccines to India. He stated, "The problem is right now we will have to make sure we have other vaccines like Novavax and others coming on, probably, and I think we'll be in a position to be able to share vaccines as well as knowhow with other countries who are in real need."

These comments seem to indicate that the U.S. government thinks that EUA for Novavax's COVID-19 vaccine is likely. Based on the high efficacy and solid safety profile seen in the clinical results that Novavax has already announced, the company's prospects of winning authorization certainly appear to be quite good.

Now what

Novavax hasn't won any EUAs for its COVID-19 vaccine yet. However, that could change in the near future. While an EUA is obviously the biggest potential catalyst to look forward to, it's also possible that the company could secure additional supply deals over the next few months.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$63.54 (-1.17%) $0.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.